Toxicity and management in chimeric antigen receptor T-cell therapy
10.3969/j.issn.1000-3606.2017.05.015
- VernacularTitle:嵌合抗原受体T细胞疗法的不良反应与治疗
- Author:
Guanhua HU
- Keywords:
chimeric antigen receptor T-cell therapy;
toxicity;
tumor
- From:
Journal of Clinical Pediatrics
2017;35(5):384-388,393
- CountryChina
- Language:Chinese
-
Abstract:
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated its clinical efficacy in hematologic malignancies with evident responses when targeting solid tumors. However, CAR T cells therapy also has the capacity to elicit expected and unexpected toxicities including cytokine release syndrome, neurologic toxicity, on target/off tumor recognition, and anaphylaxis. Theoretical toxicities include clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells therapy and strategies to cope with it.
